Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):755–762. doi: 10.1128/aac.40.3.755

Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.

L Rabin 1, M Hincenbergs 1, M B Moreno 1, S Warren 1, V Linquist 1, R Datema 1, B Charpiot 1, J Seifert 1, H Kaneshima 1, J M McCune 1
PMCID: PMC163193  PMID: 8851606

Abstract

We have developed standardized procedures and practices for infection of SCID-hu Thy/Liv mice with human immunodeficiency virus type 1 for the prophylactic administration of antiviral compounds and for evaluation of the antiviral effect in vivo. Endpoint analyses included quantitation of viral load by intracellular p24 enzyme-linked immunosorbent assay, DNA PCR for the presence of proviral genomes, flow cytometry to measure the representation of CD4+ and CD8+ cells, and cocultivation for the isolation of virus. Efficacy tests in this model are demonstrated with the nucleoside analogs zidovudine and dideoxyinosine and with the nonnucleoside reverse transcriptase inhibitor nevirapine. This small-animal model should be particularly useful in the preclinical prioritization of lead compounds within a common chemical class, in the evaluation of alternative in vivo dosing regimens, and in the determination of appropriate combination therapy in vivo.

Full Text

The Full Text of this article is available as a PDF (236.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986 Aug;59(2):284–291. doi: 10.1128/jvi.59.2.284-291.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aldrovandi G. M., Feuer G., Gao L., Jamieson B., Kristeva M., Chen I. S., Zack J. A. The SCID-hu mouse as a model for HIV-1 infection. Nature. 1993 Jun 24;363(6431):732–736. doi: 10.1038/363732a0. [DOI] [PubMed] [Google Scholar]
  3. Bonyhadi M. L., Rabin L., Salimi S., Brown D. A., Kosek J., McCune J. M., Kaneshima H. HIV induces thymus depletion in vivo. Nature. 1993 Jun 24;363(6431):728–732. doi: 10.1038/363728a0. [DOI] [PubMed] [Google Scholar]
  4. Cheeseman S. H., Hattox S. E., McLaughlin M. M., Koup R. A., Andrews C., Bova C. A., Pav J. W., Roy T., Sullivan J. L., Keirns J. J. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother. 1993 Feb;37(2):178–182. doi: 10.1128/aac.37.2.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Datema R., Rabin L., Hincenbergs M., Moreno M. B., Warren S., Linquist V., Rosenwirth B., Seifert J., McCune J. M. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother. 1996 Mar;40(3):750–754. doi: 10.1128/aac.40.3.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Clercq E. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med Res Rev. 1993 May;13(3):229–258. doi: 10.1002/med.2610130303. [DOI] [PubMed] [Google Scholar]
  7. DiMasi J. A., Hansen R. W., Grabowski H. G., Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991 Jul;10(2):107–142. doi: 10.1016/0167-6296(91)90001-4. [DOI] [PubMed] [Google Scholar]
  8. Flexner C., Barditch-Crovo P. A., Kornhauser D. M., Farzadegan H., Nerhood L. J., Chaisson R. E., Bell K. M., Lorentsen K. J., Hendrix C. W., Petty B. G. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother. 1991 Dec;35(12):2544–2550. doi: 10.1128/aac.35.12.2544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gao W. Y., Shirasaka T., Johns D. G., Broder S., Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 1993 May;91(5):2326–2333. doi: 10.1172/JCI116463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hargrave K. D., Proudfoot J. R., Grozinger K. G., Cullen E., Kapadia S. R., Patel U. R., Fuchs V. U., Mauldin S. C., Vitous J., Behnke M. L. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem. 1991 Jul;34(7):2231–2241. doi: 10.1021/jm00111a045. [DOI] [PubMed] [Google Scholar]
  11. Havlir D., Cheeseman S. H., McLaughlin M., Murphy R., Erice A., Spector S. A., Greenough T. C., Sullivan J. L., Hall D., Myers M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995 Mar;171(3):537–545. doi: 10.1093/infdis/171.3.537. [DOI] [PubMed] [Google Scholar]
  12. Kaneshima H., Shih C. C., Namikawa R., Rabin L., Outzen H., Machado S. G., McCune J. M. Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4523–4527. doi: 10.1073/pnas.88.10.4523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kaneshima H., Su L., Bonyhadi M. L., Connor R. I., Ho D. D., McCune J. M. Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol. 1994 Dec;68(12):8188–8192. doi: 10.1128/jvi.68.12.8188-8192.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koyanagi Y., Miles S., Mitsuyasu R. T., Merrill J. E., Vinters H. V., Chen I. S. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science. 1987 May 15;236(4803):819–822. doi: 10.1126/science.3646751. [DOI] [PubMed] [Google Scholar]
  15. Krowka J. F., Sarin S., Namikawa R., McCune J. M., Kaneshima H. Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol. 1991 Jun 1;146(11):3751–3756. [PubMed] [Google Scholar]
  16. McCune J. M., Namikawa R., Kaneshima H., Shultz L. D., Lieberman M., Weissman I. L. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988 Sep 23;241(4873):1632–1639. doi: 10.1126/science.241.4873.1632. [DOI] [PubMed] [Google Scholar]
  17. McCune J. M., Namikawa R., Shih C. C., Rabin L., Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science. 1990 Feb 2;247(4942):564–566. doi: 10.1126/science.2300816. [DOI] [PubMed] [Google Scholar]
  18. Namikawa R., Kaneshima H., Lieberman M., Weissman I. L., McCune J. M. Infection of the SCID-hu mouse by HIV-1. Science. 1988 Dec 23;242(4886):1684–1686. doi: 10.1126/science.3201256. [DOI] [PubMed] [Google Scholar]
  19. Namikawa R., Weilbaecher K. N., Kaneshima H., Yee E. J., McCune J. M. Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med. 1990 Oct 1;172(4):1055–1063. doi: 10.1084/jem.172.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shelton M. J., O'Donnell A. M., Morse G. D. Didanosine. Ann Pharmacother. 1992 May;26(5):660–670. doi: 10.1177/106002809202600511. [DOI] [PubMed] [Google Scholar]
  21. Stanley S. K., McCune J. M., Kaneshima H., Justement J. S., Sullivan M., Boone E., Baseler M., Adelsberger J., Bonyhadi M., Orenstein J. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med. 1993 Oct 1;178(4):1151–1163. doi: 10.1084/jem.178.4.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Su L., Kaneshima H., Bonyhadi M., Salimi S., Kraft D., Rabin L., McCune J. M. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity. 1995 Jan;2(1):25–36. doi: 10.1016/1074-7613(95)90076-4. [DOI] [PubMed] [Google Scholar]
  23. Vandekerckhove B. A., Baccala R., Jones D., Kono D. H., Theofilopoulos A. N., Roncarolo M. G. Thymic selection of the human T cell receptor V beta repertoire in SCID-hu mice. J Exp Med. 1992 Dec 1;176(6):1619–1624. doi: 10.1084/jem.176.6.1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vandekerckhove B. A., Krowka J. F., McCune J. M., de Vries J. E., Spits H., Roncarolo M. G. Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. J Immunol. 1991 Jun 15;146(12):4173–4179. [PubMed] [Google Scholar]
  25. Williams L. M., Cloyd M. W. Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology. 1991 Oct;184(2):723–728. doi: 10.1016/0042-6822(91)90442-e. [DOI] [PubMed] [Google Scholar]
  26. Witvrouw M., Pauwels R., Vandamme A. M., Schols D., Reymen D., Yamamoto N., Desmyter J., De Clercq E. Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob Agents Chemother. 1992 Dec;36(12):2628–2633. doi: 10.1128/aac.36.12.2628. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES